Velcade Side Effects

Velcade (bortezomib) is an anti-cancer drug treatment administered by IV. It is indicated for the treatment of two diseases: multiple myeloma and mantle cell lymphoma. It was first approved by the US Food & Drug Administration in 2003. In this entry we're citing the most commonly reported side effects of Velcade along with side effects of Velcade considered serious enough that they demand medical attention.

Common Side Effects of Velcade

The following side effects are considered to be common side effects of taking Velcade. This shouldn't be taken to mean that every person receiving the treatment will experience any or all of these side effects. Some will experience none; others, perhaps more than their share.

  • Joint pain
  • Bone pain
  • Muscle pain
  • Constipation or diarrhea
  • Nausea or stomach upset
  • Feeling tired
  • Insomnia or interrupted sleep
  • Dizziness, lightheadedness, headache
  • Appetite loss

Serious Side Effects of Velcade

The following serious side effects might occur as a result of receiving Velcade. If they do, one should seek immediate medical attention:

  • Severe allergic reactions (this could include a rash, itching, hives, problems breathing, chest tightness, swelling of the mouth, face, lips, or tongue)
  • Vision changes (blurred or loss of vision)
  • Peripheral neuropathy (burning, numb pain in hands or feet)
  • Chest pain, shortness of breath
  • Persistent diarrhea or constipation
  • Vomiting or stomach pain
  • Signs of infection including cough, chills, fever, sore throat
  • Sluggishness or slurred speech
  • Persistent muscle pain, cramping, or weakness
  • Urine changes (in amount or change to dark-colored urine)
  • Rapid or irregular heartbeat
  • Changes in mood
  • Suicidal thoughts
  • Fainting, confusion, seizure
  • Persistent headache
  • Sudden weight gain
  • Swelling and / or pain in the feet, ankles, legs
  • Yellowing of the skin or the eyes

More Articles

More Articles is pleased to have the Lymphoma Information Network in the family of associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics


At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...